Eliminating Modifiable Risk Factors Lowers Bleeding Risk in Patients With Cancer, VTE, Study Finds | ASH Clinical News | American Society of Hematology

Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. Anemia and hypertension were the two modifiable risk factors most closely related to anticoagulant-associated bleeding risk in patients with cancer, according to findings from a large database analysis that will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The study suggests that eliminating these and other risk factors that are within the patient’s control could substantially

Read the full article here

Source: ashpublications.org

Categories: Oncologists1, General Medicine News

Tags: Anemia,hypertension,anticoagulant,bleeding,cancer,ASH24

Tweets with this article

ASH Clinical News

#Anemia and #hypertension were the modifiable risk factors most closely related to #anticoagulant-associated #bleeding risk in patients with #cancer, and the elimination of both brought a ~19% reduction in the probability of bleeding after one year: https://t.co/CxIqPrzZmN #ASH24

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC

Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.

OncLive.com January 5, 2025

FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC

The FDA has issued a CRL to the BLA seeking approval of subcutaneous amivantamab for use in patients with EGFR-mutated non–small cell lung cancer.

OncLive.com January 5, 2025

Advanced CML Patients Treated With Novel Three-Drug… : Oncology Times

An abstract is unavailable.

Oncology Times January 5, 2025

Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials

Investigators hope to add a treatment option that has the potential to produce superior efficacy vs present ROS1 inhibitors for patients with ROS1+ NSCLC.

OncLive.com January 5, 2025

Aspirin is associated with lower risk of pancreatic cancer and cancer-related mortality in patients with diabetes mellitus

Background Patients with type 2 diabetes mellitus (T2DM) have higher pancreatic cancer (PC) risk. While aspirin has chemopreventive effects on digestive cancers, its effect on…

OncoAlert January 4, 2025

NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers

NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.

OncLive.com January 4, 2025

Novel CAR T-Cell Therapy Trial Advances to Third Cohort in Ovarian Cancer

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its third cohort.

Targeted Oncology January 4, 2025

Fertility Counseling and Preservation in Patients With NHL | Blood Cancers Today

Researchers say barriers such as time constraints and financial limitations complicate fertility counseling and preservation for patients with lymphoma.

Blood Cancers Today January 4, 2025

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care.

OncLive.com January 4, 2025

Immune Checkpoint Inhibitors: 10-Year Results in Melanoma Are Now Out – Let’s Reflect on These Impressive Advances.

Remarkable advances and remaining questions.

Piet Ost January 4, 2025

Related Articles